This is the first report of significant distal and cranial persistent muscle weakness and atrophy identified by muscle imaging in PC patients. Most reports on persistent weakness focused on proximal weakness, whereas our cases and another Japanese study [7] reported distal weakness among patients harboring a T1313M mutation in the SCN4A gene. Among the three affected members, two had mild grip weakness [7].
We reviewed case reports that mentioned neurological examinations of patients who have mutations in the SCN4A gene, and identified reports describing those positive for persistent or fixed weakness in the interictal phase. Patients described as having “no persistent/fixed weakness” or “no weakness, or no abnormal findings in neurological examination” were considered “no persistent weakness” cases. In the 44 papers analyzed (more than 76 pedigrees, 236 cases, Table 2), 42 patients (18%) had persistent weakness [3-15], 124 (53%) had no persistent weakness, and 70 (30%) had no description about weakness. Among those with persistent weakness, 4/42 (10%) were aged under 30 years, whereas 17/43 (40%) were 30 years and above, and age was unknown in 21/42 (50%). Of the 42 patients with persistent weakness, 16 had proximal weakness [3-5,10-12], five had mild distal hand weakness [6, 10], and there was no description regarding weakness distribution for 26 patients [7, 9]. Among 29 patients carrying the SCN4A T1313M mutation, 3/29 had persistent weakness [6, 10], 16/29 had no weakness, and no description was provided for 10/29.
The marked persistent weakness, muscle atrophy, and fatty changes observed in our cases reveal the myopathic nature of the disease. As Bednardz suggested [12], the pathogenesis of sodium-channel myopathies may involve increased sodium influx and osmotic edema that strangulate T-tubules, leading to fiber necrosis and stimulation of new T-tubule proliferation, vacuolar formation [14, 15], and hyperosmotic stress with mitochondrial degeneration [16]. Persistent weakness was more prevalent among patients aged over 30 years than those under 30 years (Tables 2 and 3). Recurrent myofiber stress may responsible for fiber damage due to necrosis.
In this study, we were able to detect both muscle atrophy and fatty replacement by MRI and CT imaging. An ultrasound study of 19 sodium channelopathy cases, including 10 PC cases, revealed increased echointensity in the biceps brachii and forearm flexors [17]. Our study provides further detail by showing that flexor digitorum superficialis and flexor digitorum profundus muscles were strongly involved among forearm flexors. These findings are compatible with the observations of marked finger weakness, facial muscle atrophy, and fatty changes. Moreover, muscles with severe transient weakness, such as finger, facial, and masseter muscles, were markedly myopathic among muscles.
Case III-2 presents a remarkable case in that it is the first PC patient who presented with strabismus and an arched palate. A few reports have been published regarding strabismus among SCN4A-related myotonia cases, but none of the cases were PC patients [9, 18]. Strabismus and/or diplopia was reported in 47% of children with SCN4A-related myotonia among those with sodium channelopathies [9], indicating an overlap in phenotype. Previous reports on facial involvement and arched palate involved a myopathy patient with a recessive loss-of-function mutation who did not present with myotonic features among those carrying SCN4A mutations [19, 20]. Severe facial muscle involvement may potentially explain the arched palate.
The paramyotonia observed in our patients improved with acetazolamide chloride and, similar to previous reports [21-23], we clearly described the electrophysiological interval changes. As the pathogenesis of muscle damage resulted from functional abnormalities in NaV1.4, improvement of these abnormalities may help counter persistent weakness.
In conclusion, PC patients harboring SCN4A mutations can present with persistent weakness of distal hand and cranial muscles. Phenotype varies even within a family and with age. Therapeutic approaches may counter the progression of persistent weakness.